A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Lanifibranor (Primary)
- Indications Systemic scleroderma
- Focus Proof of concept; Therapeutic Use
- Acronyms FASST
- Sponsors Inventiva Pharma
- 22 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
- 17 Oct 2017 According to an Inventiva Pharma media release, headline results from this trial are expected in early 2019.
- 17 Oct 2017 Status changed from recruiting to active, no longer recruiting according to an Inventiva Pharma media release.